Research Use Only. The information presented here is for scientific and educational purposes. These compounds are not intended for human consumption, self-administration, or therapeutic use.
Introduction
Selank is a synthetic heptapeptide that has become a frequent subject of neuropharmacology research because of its close structural relationship to tuftsin, a naturally occurring immunopeptide derived from the Fc region of immunoglobulin G. Investigators studying the Selank mechanism generally focus on how a short, tuftsin-derived sequence interacts with central signaling systems, particularly the GABAergic pathway and the monoamine networks that laboratory models associate with anxiolytic-like behavior. First characterized at the Institute of Molecular Genetics of the Russian Academy of Sciences, Selank is studied as a regulatory peptide rather than a classical single-receptor agonist.
This article summarizes what preclinical and in-vitro literature reports about the studied targets and pathways of Selank. The emphasis throughout is mechanistic: the amino acid sequence, the proposed stabilization chemistry, and the neurotransmitter systems that researchers have measured in animal and cell models. Nothing here describes human use. The compound is offered strictly for laboratory investigation, and all discussion below reflects experimental observations recorded in the scientific literature, not clinical outcomes.
Molecular Identity and Tuftsin Origins
The defining feature of Selank is that it is an engineered analog of tuftsin, the tetrapeptide Thr-Lys-Pro-Arg. Tuftsin occurs naturally as a proteolytic fragment of the heavy chain of immunoglobulin G and has been studied for decades as an immunomodulatory signal. Selank extends this parent sequence with a Pro-Gly-Pro tripeptide at the carboxyl terminus, producing the heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro.
Why the Pro-Gly-Pro Extension Matters
Native tuftsin is rapidly hydrolyzed by peptidases, which limits how long it can act in a biological system. The added Pro-Gly-Pro motif is the design element most often cited in the literature as the reason Selank shows greater metabolic stability than tuftsin itself. Proline-rich termini are relatively resistant to aminopeptidase and carboxypeptidase activity, so the extension is understood to slow enzymatic breakdown while preserving the tuftsin pharmacophore that engages downstream signaling.
Reported Molecular Attributes
The following identity values reflect commonly reported laboratory attributes and are provided for comparison only.
| Attribute | Reported Value |
|---|---|
| Compound class | Synthetic heptapeptide (tuftsin analog) |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro |
| Sequence length | 7 residues |
| Molecular formula | C33H57N11O9 |
| Molecular weight | approximately 751.9 g/mol |
| Parent peptide | Tuftsin (Thr-Lys-Pro-Arg) |
| Research origin | Institute of Molecular Genetics, Russian Academy of Sciences |
Laboratories that source the peptide for structural or receptor-binding work typically confirm these attributes against a certificate of analysis. Our guide to reading a peptide COA explains how sequence identity and purity are verified by mass spectrometry and HPLC, and each batch is documented on the certificates page.
GABAergic Signaling in Selank Research
A large share of the mechanistic interest in Selank centers on the gamma-aminobutyric acid (GABA) system, the principal inhibitory neurotransmitter network in the mammalian central nervous system. Because GABAergic tone is closely tied to models of neural excitability, researchers have examined whether a tuftsin-derived peptide can shift the expression or activity of components in this pathway.
Gene Expression Findings
Gene expression studies conducted at the Institute of Molecular Genetics have reported that Selank can alter transcription of genes linked to GABA-A receptor subunits and to enzymes involved in GABA turnover in rodent brain tissue. Rather than acting as a direct ligand at the receptor, the peptide is generally described in this literature as a modulator that influences the broader expression profile of the inhibitory system. This regulatory, network-level framing is a recurring theme in how the Selank mechanism is interpreted.
Relationship to Excitability Models
Investigators have paired these transcriptional observations with behavioral paradigms in animals to ask whether measured changes in GABAergic markers track with reduced anxiety-like responses. The consistent research narrative is correlational and preclinical: shifts in inhibitory signaling markers are recorded alongside behavioral readouts, without any claim of a therapeutic effect in humans.
Anxiolytic Pathways and Neurotransmitter Modulation
Beyond GABA, the Selank mechanism is studied across several monoamine and neuropeptide systems. These investigations are consistently framed as anxiolytic-like activity in animal models, and the peptide remains a research compound: it is for research use only, not for human consumption.
Enkephalin Stabilization
One of the most cited biochemical observations is that Selank appears to slow the enzymatic degradation of enkephalins, the endogenous opioid-family peptides, in blood plasma. By inhibiting the peptidases that break these signals down, Selank is proposed to extend the lifetime of regulatory peptides that participate in the stress and mood-related circuits studied in rodents.
Monoamine and Neurotrophic Markers
Preclinical reports also describe measured changes in serotonin metabolism and in the balance of dopamine and noradrenaline in specific brain regions of laboratory animals. Additional studies have recorded shifts in brain-derived neurotrophic factor (BDNF) expression, a marker often examined in the context of neural plasticity. Taken together, this body of work positions Selank as a multi-target regulatory peptide rather than a single-receptor agent.
Because Selank and the related peptide Semax both emerged from the same research program, laboratories frequently study them in parallel. The Semax research peptide shares a comparable proline-stabilized architecture and is a common reference point in nootropic peptide investigations.
Selank in Comparative Peptide Context
Placing Selank alongside its parent peptide and its research sibling clarifies why its sequence is of interest. The values below reflect commonly reported laboratory attributes and are provided for comparison only.
| Peptide | Sequence | Length | Approx. MW | Studied Research Focus |
|---|---|---|---|---|
| Tuftsin | Thr-Lys-Pro-Arg | 4 residues | 500.6 g/mol | Immunomodulatory signaling |
| Selank | Thr-Lys-Pro-Arg-Pro-Gly-Pro | 7 residues | 751.9 g/mol | GABAergic and anxiolytic pathways |
| Semax | Met-Glu-His-Phe-Pro-Gly-Pro | 7 residues | 813.9 g/mol | Neurotrophic and nootropic pathways |
The shared Pro-Gly-Pro tail across Selank and Semax illustrates a common design strategy: take a short endogenous signaling motif (tuftsin for Selank, a fragment of ACTH for Semax) and append a proline-rich extension to increase stability. This comparative view is why research-grade Selank and Semax are so often catalogued together within the broader research peptide catalog.
Frequently Asked Questions
What is the Selank mechanism of action?
In preclinical research, Selank is described as a regulatory peptide that influences the GABAergic system, slows the enzymatic degradation of enkephalins, and shifts monoamine and BDNF markers in animal models. It is generally characterized as a multi-target modulator rather than a single-receptor agonist.
How is Selank related to tuftsin?
Selank is a synthetic analog of tuftsin, the tetrapeptide Thr-Lys-Pro-Arg. It adds a Pro-Gly-Pro extension at the C-terminus, forming a heptapeptide that laboratory studies report is more resistant to peptidase breakdown than native tuftsin.
Does Selank act directly on GABA receptors?
The published literature more often describes Selank as influencing the expression of GABA-A receptor subunits and related genes than as a direct receptor ligand. Its mechanism is typically interpreted at the level of network and transcriptional regulation in rodent studies.
What is the difference between Selank and Semax?
Both are proline-stabilized heptapeptides from the same Russian research program, but they derive from different parent signals. Selank is built from tuftsin and is studied for GABAergic and anxiolytic pathways, while Semax derives from an ACTH fragment and is studied for neurotrophic and nootropic pathways.
What is the molecular weight of Selank?
Selank has a reported molecular weight of approximately 751.9 g/mol, with the molecular formula C33H57N11O9 and the seven-residue sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro.
Is Selank approved for human use?
No. Selank is supplied strictly as a research chemical for laboratory investigation. It is not intended for human consumption, self-administration, or therapeutic use, and the mechanistic data discussed here come from preclinical and in-vitro studies only.
References and Further Reading
- Zozulya AA and colleagues, Institute of Molecular Genetics (Russian Academy of Sciences), research on the anxiolytic peptide Selank. PubMed: selank anxiolytic peptide
- Foundational work on tuftsin as an immunomodulatory tetrapeptide fragment of immunoglobulin G. PubMed: tuftsin peptide immunology
- Studies examining Selank and GABAergic receptor gene expression. PubMed: selank GABA receptor
- Kolomin T and colleagues, gene expression profiling following regulatory peptide administration. PubMed: selank gene expression
- Reports on Selank, serotonin, and monoamine metabolism in brain tissue. PubMed: selank serotonin brain
- Investigations of Selank and enkephalin degradation in plasma. PubMed: selank enkephalin degradation
- Myasoedov NF and colleagues, comparative studies of the regulatory peptides Selank and Semax. PubMed: selank semax regulatory peptides
